Evidence map›Paper›PMID 28322750›Full record

ArticleBrain research2017

Supradural inflammatory soup in awake and freely moving rats induces facial allodynia that is blocked by putative immune modulators.

Julie Wieseler, Amanda Ellis, Andrew McFadden, Kendra Stone, Kimberley Brown, Sara Cady, Leandro F Bastos, David Sprunger, Niloofar Rezvani, Kirk Johnson and 3 more

3 registry-linked trialsOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03061734 phase2completednot on this map

A Clinical Trial to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine

TypeinterventionalSponsorAllodynic Therapeutics, IncRan2017 to 2018Enrolled92ConditionsMigraine With or Without AuraArmsNaltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo
NCT05685225 phase2withdrawnnot on this mapstarted 2025, after this paper: background citation

Safety and Efficacy of Naltrexone/Acetaminophen for the Acute Treatment of Migraine: A Single-Site, Phase 2 Randomized Trial

TypeinterventionalSponsorAllodynic Therapeutics, IncRan2025 to 2025Enrolled0ConditionsMigraineArmsStage 1: Naltrexone/Acetaminophen, Stage 1: Naltrexone, Stage 1: Acetaminophen, Stage1: Placebo, Stage 2: Naltrxone/Acetaminophen high dose
NCT06245902 phase2completednot on this map

A Clinical Trial to Assess a Single Dose of Low-Dose Naltrexone and Acetaminophen Combination and Its Components in the Acute Treatment of Migraine

TypeinterventionalSponsorAllodynic Therapeutics, IncRan2017 to 2018Enrolled92ConditionsMigraine With or Without AuraArmsNaltrexone and Acetaminophen, Naltrexone and Acetaminophen-High Dose, Naltrexone Alone (regular dose), Acetaminophen Alone, Matching Placebo
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Purines in Pain as a Gliopathy.Frontiers in pharmacology · 2021
    Article
  14. Article
  15. Review
  16. Effect of Pregnancy on TMJ Nociception in Rats.Kou qiang yi xue yan jiu = Journal of oral science research · 2018
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Julie WieselerDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Amanda EllisDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Andrew McFaddenDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Kendra StoneDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Kimberley BrownDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Sara CadyDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Leandro F BastosDepartamento de Fisiologia e Biofisica, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Avenida Antonio Carlos, 6627, CEP 31270-901 Minas Gerais, Brazil.
David SprungerDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Niloofar RezvaniDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Kirk JohnsonMediciNova Inc, 4350 La Jolla Village Dr., #950, San Diego, CA, USA.
Kenner C RiceDrug Design and Synthesis Section, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD, USA.
Steven F MaierDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA.
Linda R WatkinsDepartment of Psychology and Neuroscience, Center for Neuroscience, University of Colorado at Boulder, Boulder, CO, USA. Electronic address: linda.watkins@colorado.edu.
University of Colorado Boulder · USMediciNova (United States) · USNational Institute on Drug Abuse · USUniversidade Federal de Minas Gerais · BR

Funding

Medicinal Chemistry of Drugs Acting on Toll-like ReceptorsZIADA000530 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI RICE, KENNER · 2009 to 2020
$4.0M
Preventing Transition of Acute-to-Chronic Neuropathic Pain: Models, Mechanisms &R01DE021966 · NIDCR · UNIVERSITY OF COLORADO · PI BARTH, DANIEL S., FLESHNER, MONIKA · 2011 to 2015
$2.0M
NIDCR NIH HHS R01 DE021966
6 · The paper itself

Abstract

Facial allodynia is a migraine symptom that is generally considered to represent a pivotal point in migraine progression. Treatment before development of facial allodynia tends to be more successful than treatment afterwards. As such, understanding the underlying mechanisms of facial allodynia may lead to a better understanding of the mechanisms underlying migraine. Migraine facial allodynia is modeled by applying inflammatory soup (histamine, bradykinin, serotonin, prostaglandin E2) over the dura. Whether glial and/or immune activation contributes to such pain is unknown. Here we tested if trigeminal nucleus caudalis (Sp5C) glial and/or immune cells are activated following supradural inflammatory soup, and if putative glial/immune inhibitors suppress the consequent facial allodynia. Inflammatory soup was administered via bilateral indwelling supradural catheters in freely moving rats, inducing robust and reliable facial allodynia. Gene expression for microglial/macrophage activation markers, interleukin-1β, and tumor necrosis factor-α increased following inflammatory soup along with robust expression of facial allodynia. This provided the basis for pursuing studies of the behavioral effects of 3 diverse immunomodulatory drugs on facial allodynia. Pretreatment with either of two compounds broadly used as putative glial/immune inhibitors (minocycline, ibudilast) prevented the development of facial allodynia, as did treatment after supradural inflammatory soup but prior to the expression of facial allodynia. Lastly, the toll-like receptor 4 (TLR4) antagonist (+)-naltrexone likewise blocked development of facial allodynia after supradural inflammatory soup. Taken together, these exploratory data support that activated glia and/or immune cells may drive the development of facial allodynia in response to supradural inflammatory soup in unanesthetized male rats.

Indexed as

AnimalsDura MaterEncephalitisHyperalgesiaIndolizinesInflammation MediatorsMacrophagesMaleMicrogliaMigraine DisordersMinocyclinePyrazolesPyridinesRats, Sprague-DawleyTrigeminal Caudal NucleusibudilastIndolizinesInflammation MediatorsMinocyclinePyrazolesPyridinesDuraHeadacheInterleukin-1MigraineOX42Tumor necrosis factor alpha

Identifiers

PMID28322750
PMCPMC6668623
OpenAlexW2595088977

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.